Status:
COMPLETED
Intradermal Versus Intramuscular Trivalent Influenza Vaccine in Adult Lung Transplant Recipients
Lead Sponsor:
University of Alberta
Collaborating Sponsors:
University of Lausanne Hospitals
Conditions:
Influenza Virus
Influenza Vaccine
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
The influenza virus, commonly called the flu, is a common source of infection in lung transplant patients and can often lead to pneumonia and possibly rejection. The annual influenza vaccine is the mo...
Detailed Description
The annual influenza vaccine is suggested for immunocompromised patients. However, the immunogenic response to this vaccine is suboptimal and ranges from 15-70%. In lung transplant recipients, respons...
Eligibility Criteria
Inclusion
- Age ≥ 18
- Greater than 3 months post-transplant
- Outpatient status
Exclusion
- Has already received influenza vaccination for 2008-2009 season
- Egg allergy
- Previous life-threatening reaction to influenza vaccine (i.e. Guillain Barre Syndrome)
- On anticoagulants such as warfarin that precludes intramuscular injection
- Ongoing therapy for rejection
- Febrile illness in the past two weeks
- Unable to provide informed consent
- Unable to comply with study protocol
Key Trial Info
Start Date :
October 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2010
Estimated Enrollment :
85 Patients enrolled
Trial Details
Trial ID
NCT00760175
Start Date
October 1 2008
End Date
February 1 2010
Last Update
May 27 2015
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alberta Hospital
Edmonton, Alberta, Canada, T6G 2E1
2
University Hospital of Lausanne
Lausanne, Switzerland